Crinetics Pharma COO to step down
Source: SeekingAlpha
2026-03-23 15:54:05 ET
More on Crinetics Pharmaceuticals
- Crinetics Pharmaceuticals, Inc. (CRNX) Presents at TD Cowen 46th Annual Health Care Conference - Slideshow
- Crinetics Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
- Most oversold mid-cap healthcare stocks on Wall Street amid Middle East disruptions
- Crinetics outlines $600M–$650M 2026 operating expense plan as PALSONIFY launch accelerates
Read the full article on Seeking Alpha
For further details see:
Crinetics Pharma COO to step down
Crinetics Pharmaceuticals Inc.
NASDAQ: CRNX
CRNX Trading
2.51% G/L:
$37.23 Last:
1,247,931 Volume:
$35.83 Open:
CRNX Latest News
March 27, 2026 08:16:18 pm
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More
March 26, 2026 04:05:00 pm
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify(TM) (Paltusotine) in Acromegaly
February 26, 2026 04:05:00 pm
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CRNX Stock Data
$4,886,200,047
97,468,580
0.1%
86
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
